Future Market Insights (FMI), a leading market intelligence and consulting firm, has recently released a comprehensive study projecting a remarkable 5.97% Compound Annual Growth Rate (CAGR) for the Global Autosomal Dominant Polycystic Kidney Disease Treatment Industry demand from 2023 to 2033. This anticipated growth is set to propel the market to a valuation of US$ 2,140 million by the end of the forecast period.
The surge in market demand is attributed to the availability of special regulatory designations, fostering an environment conducive to market expansion. Additionally, the rise in Autosomal Dominant Polycystic Kidney Disease (ADPKD) therapy studies is proving instrumental in driving business prosperity.
Request a Sample of this Report Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-16623
Drug companies stand to benefit from market exclusivity for a set length of time, as well as clinical trial tax benefits and treatment assistance, which can help increase the market. Technological advances and the development of a diverse range of medications are also likely to drive market expansion, allowing physicians to better support ADPKD patients. Government activities aiming at improving knowledge of ADPKD therapy, such as those done by the Polycystic Kidney Foundation, are also projected to support market expansion.
However, the high cost of ADPKD treatment remains a significant impediment, as does the industry’s scarcity of trained professionals.
Key Takeaways from the Global Autosomal Dominant Polycystic Kidney Disease Treatment Industry
- With a market share of over 39.5% by the end of the forecast period, North America is expected to lead the industry.
- Over the forecast period, East Asia’s market is expected to grow at the fastest rate of 6.2%.
- By the end of the projection period, pain and inflammation are estimated to account for 37.4% of the market.
- Hospital pharmacies are expected to dominate the market by 2033, accounting for 54% of the market.
“One primary factor that will lead to the expansion of the global polycystic kidney disease drug market is the increasing availability of favourable reimbursement policies. Off-label medications are majorly given to people with polycystic kidney disease,” comments an FMI analyst.
Reach Out to Our Analyst For Your Queries https://www.futuremarketinsights.com/ask-question/rep-gb-16623
Global Autosomal Dominant Polycystic Kidney Disease Treatment Industry Competitive Landscape
The Global Autosomal Dominant Polycystic Kidney Disease Treatment Industry is intensely competitive and consists of several industry players. These players are developing novel delivery systems for treating Autosomal Dominant Polycystic Kidney Disease Treatment. This is estimated to propel Autosomal Dominant Polycystic Kidney Disease Treatment market. The key players in this industry are: Otsuka Pharmaceutical, Sanofi, Reata Pharmaceuticals, Galapagos NV, Janssen Pharmaceuticals, Regulus Therapeutics, Xortx Therapeutics, AceLink Therapeutics, Inc., PanoTherapeutics, Inc., and Exelixis, Inc. Some recent developments in the market are:
- Grupo Olmos, a provider of renal care solutions, announced in July 2022 that it had purchased the renal care business of Diaverum, an Argentine renal healthcare provider. This acquisition will help the company’s renal product portfolio.
- Palladio Biosciences announced in 2020 that the first patient with autosomal dominant polycystic kidney disease has been dosed with lixivaptan, a new vasopressin V2 antagonist. They confirmed the safety of lixivaptan in these individuals who had previously stopped using tolvaptan due to liver damage.
- Aster Hospitals, one of the largest private healthcare service providers in the GCC, said in March 2019 that it had launched an awareness and screening effort to promote the prevention of chronic kidney disease through education, awareness, and early diagnosis.
- Bayer announced the launch of finerenone, a medication used to treat chronic kidney disease associated with type 2 diabetes, in India in August 2022.
- Health Canada accepted GlaxoSmithKline’s New Drug Submission for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment of chronic kidney disease anaemia, in July 2022.
More Valuable Insights Available
Future Market Insights offers an unbiased analysis of the global Autosomal Dominant Polycystic Kidney Disease Treatment market, providing historical data for 2018 to 2022 and forecast statistics from 2023 to 2033.
Click Here To Buy Your Full Report https://www.futuremarketinsights.com/checkout/16623
Key Segments Profiled in the Global Autosomal Dominant Polycystic Kidney Disease Treatment Industry Survey
By Treatment Type:
- Pain & Inflammation Treatment
- Kidney Stone Treatment
- Urinary Tract Infection Treatment
- Kidney Failure Treatment
By End User:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
